This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research ...

With many PBMs receiving scrutiny, smaller startups that bill themselves as more transparent are seeing interest from employers in the state and nationally.

In this final video of a three-part video series, Joshua Fredell, Pharm.D., senior vice president at CVS Caremark and a ...

The lawsuit alleges civil violations of the Racketeer Influenced and Corrupt Organizations Act, or RICO, the Connecticut ...

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS Health, the parent of PBM juggernaut CVS Caremark, won’t presently add Gilead’s twice-yearly pre-exposure prophylaxis (PrEP) drug Yeztugo to its commercial plans or Affordable Care Act ...

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...

Caremark was found liable in June, and Philadelphia federal court Chief Judge Mitchell Goldberg ordered the company to pay $95 million in damages, deferring final rulings on penalties.

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the federal False Claims Act.